文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

双载体rAAVrh8基因治疗GM2神经节苷脂沉积症:1/2期试验

Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.
PubMed 文献 · Nat Med · 2025-08-15

这项1/2期单剂量剂量递增试验在9例Tay-Sachs病和Sandhoff病患儿(6例婴儿型、3例青少年型)中评估双载体rAAVrh8-HEXA与rAAVrh8-HEXB联合双侧丘脑、枕大池及鞘内输注的安全性与生化疗效;脑脊液HexA酶活性、血清总Hex活性及GM2水平呈剂量依赖性生化纠正,婴儿型患者临床稳定且口腔喂养延长至3-3.5岁,但青少年型患者出现肌张力障碍加重并被排除继续入组。

要点

  • 脑脊液HexA酶活性、血清总Hex活性及GM2水平呈剂量依赖性生化纠正。
  • 血清Hex活性超过40 nmol h-1 ml-1,为正常下限的两倍,神经影像显示纤维束增加。
  • 纠正效果在给药后12周最大,至24周时下降;婴儿型患者临床稳定且口腔喂养延长至3-3.5岁。

核心结论

  • 双载体rAAVrh8-HEXA与rAAVrh8-HEXB联合双侧丘脑、枕大池及鞘内输注可在Tay-Sachs病和Sandhoff病患儿中实现剂量依赖性生化纠正,婴儿型患者临床稳定且口腔喂养延长至3-3.5岁,但青少年型患者出现肌张力障碍加重并被排除继续入组。

研究设计与样本

  • 1/2期、单剂量、剂量递增试验,在Tay-Sachs病和Sandhoff病患儿中评估双载体rAAVrh8-HEXA与rAAVrh8-HEXB联合双侧丘脑、枕大池及鞘内输注,共9例(6例婴儿型、3例青少年型)。
  • 四个队列间双侧丘脑注射体积与载体剂量加倍,最低剂量与既往扩展可及试验一致。

主要发现

  • 脑脊液HexA酶活性、血清总Hex活性及GM2水平呈剂量依赖性生化纠正。
  • 血清Hex活性超过40 nmol h-1 ml-1,为正常下限的两倍,神经影像显示纤维束增加。
  • 纠正效果在给药后12周最大,至24周时下降。
  • 婴儿型患者实现整体临床稳定,口腔喂养延长至3-3.5岁且无误吸。
  • 癫痫发作起病更晚、频率更低、严重程度更轻且对抗惊厥药物反应更好。

关键数值与推荐

  • 血清Hex活性超过40 nmol h-1 ml-1,为正常下限的两倍。
  • 纠正效果在给药后12周最大,至24周时下降。
  • 婴儿型患者口腔喂养延长至3-3.5岁且无误吸。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The dual rAAVrh8-HEXA and rAAVrh8-HEXB vector can restore central nervous system hexosaminidase (Hex) enzyme activity, decrease GM2 levels in cerebrospinal fluid and rescue phenotypic consequences of GM2 gangliosidosis, Tay-Sachs and Sandhoff diseases in animal models following simultaneous bi-thalamic (BiT) injections. Following up on an n = 2 expanded access trial, we initiated a phase 1/2, single-dose, dose-escalation of combined BiT, intra-cisterna magna and intrathecal infusion in children with Tay-Sachs and Sandhoff diseases (six infantile, three juvenile). The BiT injection volume and vector dose were doubled between four cohorts, with the lowest dose matching the earlier expanded access trial. Cerebrospinal fluid HexA enzyme activity, serum total Hex activity and GM2 levels showed a dose-dependent biochemical correction of the disease. Serum Hex activity surpassed 40 nmol h-1 ml-1, two times the lower limit of normal, and neuroimaging demonstrated increased fiber tracts. Correction was greatest at 12 weeks, but in decline by 24 weeks postdosing. Infantile patients experienced global clinical stabilization and prolonged oral feeding without aspiration until 3-3.5 years. Seizures had a later onset, were less frequent, less severe and more responsive to anti-convulsant medication. Adverse events were rare in infantile patients, but worsening dystonia was observed in juvenile patients, who were excluded from ongoing enrollment. ClinicalTrials.gov registration: NCT04669535 and NCT06614569 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Eichler F, Cataltepe OI, Daci R, et al. Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial. Nat Med. 2025. PMID: 40817303. doi:10.1038/s41591-025-03822-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。